Good day, everyone. Welcome to Revance Therapeutics' second quarter 2021 financial results and corporate update conference call. I would now like to turn the conference over to Jessica Serra, Head of Investor Relations and ESG for Revance. Please go ahead. Thank you, Anne. Joining us on the call today from Revance are President and Chief Executive Officer, Mark Foley, Chief Financial Officer, Toby Schilke, Chief Operating Officer and President of R&D and Product Operations, Dr. Abhay Joshi, Chief Commercial Officer, Aesthetics and Therapeutics, Dustin Sjuts, and President of Innovation and Technology, Aubrey Rankin. During this conference call, management will make forward-looking statements, including statements related to the clinical development of our product candidates, our business strategy, plant operations, commercialization plans, potential benefits of our drug product candidates and technologies, the launch of the next generation FinTech platform, the timing of any potential approval of DaxibotulinumtoxinA for Injection, 2021 guidance, expected cash runway, and the various industry trends. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. On today's call, we will present both GAAP and non-GAAP financial measures. A reconciliation of non-GAAP to the GAAP measures is included in the earnings release. For that, I will turn the call over to Mark Foley. Mark? Thank you, Jessica. Good afternoon, everyone, and thank you for joining our second quarter 2021 financial results conference call. We're very pleased to report strong second quarter results, highlighted by $17 million in RHA revenue, over 2,000 aesthetic accounts shared across products and services, and over $500 million in FinTech processing volume run rate. Our focus on execution, supported by a healthy aesthetics market, led to our third consecutive quarter of revenue growth since becoming a commercial entity and further validated our commercial launch strategy. These results would not have been possible without the entire Revance organization working together as a team. I continue to be impressed by the exceptional talent we've been able to attract to the company and by their unwavering commitment and dedication to deliver on our objectives. With the FDA having initiated their pre-approval inspection of our manufacturing facility in June, we continue to anticipate the approval of our lead product, DaxibotulinumtoxinA for Injection, for the treatment of glabellar lines this year. In the meantime, the Revance team is actively building inventory and solidifying our commercial launch plans for our innovative neuromodulator. We look forward to introducing the first true innovation in the neuromodulator category in over 30 years. Once approved, DaxibotulinumtoxinA for Injection will not only anchor our aesthetics portfolio, but also lay the foundation for our therapeutics franchise. We expect the second half of the year to be very busy and exciting, particularly as we anticipate several catalysts in our therapeutics pipeline, which I will cover later in this call. With that, let me turn the call over to Dustin, who will cover the performance of our aesthetics business in the second quarter. Dustin? Thank you, Mark. We have built a solid track record of execution since our initial commercial launch, with over 2,000 accounts across 40 states now carrying RHA Collection and/or using our payments platform. This is up from 1,500 accounts in the first quarter. Our consistent results continue to reinforce our confidence in our prestige go-to-market strategy. During the second quarter, through a combination of our sales efforts and injector education, RHA sales increased to $17 million, up from $11.6 million in the prior quarter. Growth was also complemented by a seasonally busy period for aesthetic procedures. As we've noted before, Q2 and Q4 are generally more active quarters for aesthetic procedures compared to Q1 and Q3. Given these patterns, we expect Revance's revenue growth to be moderated in Q3, particularly as our sales team ramps up their training to prepare for the potential commercial launch of DaxibotulinumtoxinA for Injection once approved. We expect a return to a seasonally stronger fourth quarter. Turning to our aesthetic FinTech platform, we're pleased to see continued growth in the platform's processing volume run rate, up from over $400 million in Q1 to over $500 million at the end of Q2. We are also on target in completing the launch of PayFac. Becoming an authorized payment facilitator entails extensive testing, controls, and regulations. It was a big undertaking for the entire organization and a significant accomplishment. We are now well-positioned to unlock substantial value in our service offering to practices. As a reminder, PayFac enables us to participate in more of the credit card processing value chain. Further, as a PayFac, we'll be able to leverage the source data to build new features and functionalities that enhance the overall value proposition of our services offering. We are now in the market beta testing our next-generation FinTech platform, which we expect to commercially launch in the fourth quarter. We're finalizing a rollout plan and look forward to sharing more details on the new platform soon. Given the technical and commercial preparations underway, we'll be moderating new account activation with the launch of the new platform. Until then, we'll include both the legacy and the new platform when accounting for our service revenue and payments processing volume run rate. Before I turn the call to Mark, I'd like to introduce a few recent key hires across Revance Aesthetics and Revance Therapeutics in support of our commercial evolution. First, as part of our commitment to developing our FinTech services segment, I'm pleased to share the appointment of Käthe Anchel as the General Manager of Financial Services in our FinTech platform. Käthe brings over 20 years of experience in designing and building successful consumer products in payments, e-commerce, and financial services at leading organizations including Groupe Québec, Citigroup and PayPal. Käthe will be instrumental in setting our long term aesthetic services strategy while also ensuring a smooth launch of our next generation FinTech platform. We're excited to have her on board and look forward to leveraging her leadership and experience as we continue to evolve and grow the aesthetic franchise. As for therapeutics, we're now at a critical inflection point. We are pivoting our focus to commercial launch preparation following strong data from a very successful phase III pivotal trial for DaxibotulinumtoxinA for Injection in the treatment of cervical dystonia. Following closely behind is our clinical program for adult limb spasticity, which is preparing for phase III. For these reasons, we're pleased to announce the appointment of Rob Bancroft as the General Manager, Therapeutics. Rob adds to the strength of our team, bringing more than 25 years of experience in healthcare and life science industries. He also has a strong background in the therapeutic toxin space. At Allergan, Rob was instrumental in leading global pipeline development strategies for Botox Therapeutic, laying the groundwork for expansion investments like spasticity, migraine, neurogenic overactive bladder. Most recently, Rob was the CEO for QMENTA, a company focused on accelerating solutions for brain diseases. Prior to that, he was Executive Vice President of Healthpoint Biotherapeutics. With his strong background and track record, Rob will help strengthen our therapeutics pipeline strategy and advance our clinical development, all while guiding our franchise through commercialization. With a strong team and infrastructure in place, we look forward to elevating the value of our therapeutics franchise and entering the growing $2.3 billion global therapeutic neuromodulator market. With that, I'll turn the call back over to Mark to discuss our upcoming pipeline milestones. Mark? Thanks, Dustin. We are anticipating two key milestones in our therapeutics pipeline in the second half of the year. As Dustin mentioned, we are currently in phase III clinical trials evaluating DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia. In the second half, we expect to share the results from our ASPEN open label long-term safety study. Afterwards, we plan on filing a supplemental Biologics License Application in 2022 with anticipated approval in 2023. Our clinical team is also preparing for a phase III program in adult upper limb spasticity. You'll recall that we completed our JUNIPER phase II study in February of this year, and our plan remains to hold an end of phase II- Commercial activities for the DaxibotulinumtoxinA for Injection. SG&A expenses include depreciation and amortization and stock-based compensation. Excluding these expenses, non-GAAP SG&A expenses were $42.4 million. Research and development expenses were $29.4 million for the second quarter, reflecting costs related to clinical trials, regulatory support for our ongoing Biologics License Application, pre-commercial manufacturing, and our FinTech platform development. R&D expenses include depreciation and amortization and stock-based compensation. Excluding these expenses, non-GAAP R&D expenses were $24.9 million. We continue to balance growth with financial discipline during the quarter, and our balance sheet remains strong heading into the second half of the year. Cash, cash equivalents, and short-term investments as of June 30, 2021, were $336.3 million, which we believe is sufficient to fund our operating plan into 2024. We reaffirmed our previously announced 2021 guidance. For approximately $71.8 million, with 76.7 million fully diluted shares, excluding the impact of convertible debt. With that, I'll turn the call back over to Mark. Thank you, Toby. In closing, we're very proud of our performance in the first half of the year and anticipate a strong finish in the second half with the potential approval of DaxibotulinumtoxinA for Injection and further advancement in our therapeutics pipeline. We also remain in a solid financial position with sufficient cash to support our growth initiatives into 2024. With that, I will now open the call up for questions. Operator? Thank you. As a reminder, to ask a question, you may press star then 1 on your telephone keypad. That's star 1 on your telephone. We will have our first question from the line of Seamus Fernandez from Guggenheim. Your line is now open. Oh, thanks very much. I'll do my 1 question and follow-up. Kick off with the 1st question. AbbVie, really, under the Allergan moniker really delivered a very strong second quarter. Congrats on your guys' second quarter. 1 thing that they commented on was that they anticipated that approximately 2/3 of the demand was regular wave demand, and then about 1/3 was pent-up. Would you guys maybe just comment on your thoughts around that statement and what it means relative to sort of the growth of the market relative to share taking as you think about it? I have 1 other follow-up question. Seamus, this is Mark Foley. I don't know that we've got any sort of better data than that. We're in launch phase, so obviously the accounts that we're dealing with represent sort of a smaller fraction of the overall market. Having said that, I would say that our focus on prestige and the high end nature of these accounts, there's definitely a pretty healthy backlog. We're talking with them. There's no doubt there's some pent-up demand. There's clearly some new consumers that are entering the market, somewhat as a Zoom effect and everything else. We feel very good that we've returned, at least for now, back to levels that were pre-pandemic and certainly we would expect that we'll continue to see overall market growth, but I don't know that we have anything additional to add. We feel very good about where we are in the market, where we are with accounts, as you can tell with the roughly 2,000 or so accounts that we're in between our products and services that we're being pretty targeted. Clearly we're seeing a nice, healthy market right now. Great. Then just as the second question, very quickly on just obviously you're expressing a high degree of confidence in the launch. So I'm assuming that the FDA inspection is going swimmingly. Maybe you could just give us a general sense of how you would encourage us to think about the launch and uptake, obviously given your premium strategy in the fourth quarter versus how we should think about the rollout through the balance, or maybe just without guiding specifically, but just kind of the rollout through the balance of 2022. Thanks. Yeah, thanks for asking that. First on the FDA process and where we're at, consistent with prior commentary, we indicated that prior to our PDUFA date, everything had been addressed except for the on-site inspection as part of our PAI. As you're aware, we press released that an inspection date had not been scheduled yet, due to the FDA delays, we were in a bit of a holding pattern waiting for that to occur. Given that this is our first drug approval, remote inspection was not a possibility, and they were going to need to physically inspect the plant. We then, in the spring, put out a press release that we'd been given an inspection date to occur before the end of Q2, and obviously in our press release and in our remarks, the FDA has shown up at our facility. We continue to feel very good that they're following sort of through with the expected inspection plan. Seamus Fernandez, I think you're sensing consistency with our tone around the expected approval before year-end, and we've taken advantage of this time to beef up sort of our readiness for the inspection and continue to advance our commercial preparation plans. In terms of the launch trajectory, we've also tried to be consistent. This will be the first time that our product has been used outside of clinical trials, and as a result, we're going to be sort of very thoughtful, intentional in the first phase of our launch, similar to what we did with the RHA Collection. I think for the balance of this year likely and post-approval, we're going to spend most of our time focusing on ensuring that we're going to get really good reproducible outcomes that are consistent with our clinical trial data, and that our commercial launch is likely to be much more of a 2022 phenomenon. That's how we're thinking about it, that there will be this sub-period post-approval, where we are going to need to spend some time with a select group of customers getting real-world commercial experience before going through a more traditional launch. Great. Thanks for the question. Thank you. Our next question comes from the line of Terence Flynn from Goldman Sachs. Your line is now open. Great, thanks for taking the questions. Maybe just one follow-up, Mark Foley, on the DAXI manufacturing side. In the past, I think you've noted about a 6 to 10-week timeline for a turnaround from the FDA. Just wondering if that's still your expectation. Obviously a strong quarter for the filler side here. Obviously breadth contributed, but just wondering what you're seeing from the reorder side of things. Thank you. Yeah. First off, we intentionally didn't give sort of a set timeframe because we're outside of the PDUFA clock, where within the PDUFA framework everything is moving towards a deadline. It's hard to know exactly that the timeframe that the agency's going to work under as it relates to the inspection. Clearly, they're trying their best, I think, to resolve any of these outstanding issues. We continue to stick to our commentary that we're focused on an approval certainly before the end of 2021 and have full preparation and build schedule going on in the interim. Regarding the filler and reorder rates, I think it's still a little early for us to make a lot of commentary around it. This is our third full quarter of launch. We still are seeing the cycle of accounts coming online, figuring out where it fits in their practice. We also expect with the approval of our neuromodulator, that's going to introduce another new dynamic in there that may change a little bit sort of the percent of the business and accounts willing to consider giving to us, which accounts might be willing to lean in that were otherwise waiting until we had a full bag. I think it's still a little bit early. Certainly, as we get visibility and have data that we think is more reflective of what the business is going to look like going forward, we're happy to share it, but we still think we're a little bit early in that process. Great, thanks. Next question? Thank you. Our next question comes from the line of Annabel Samimy from Stifel. Your line is now open. Hi, guys. Thanks for taking my question. Just a little bit more on the commercial preparations you're doing ahead of the approval. What are you able to do? You've obviously penetrated a decent amount of accounts. Is there anything that you can do outside of potential training and education, such as commercial work, contracting work, preliminary contracting, preliminary negotiation? Is there any of that stuff that can happen ahead of time that could potentially smooth the process for the launch and not pull away too much of the energy from the filler momentum that you're having? Then on the manufacturing side, I realize that you said that this is a process. So I imagine that means that there's a bit of a back and forth. If there are any issues that do come up, would you be telegraphing any of that, or is this just you're keeping it as part of the process and you're still on board for second half, and that's about all you're going to say? Thanks. First on the commercial prep, obviously in the absence of approval, there's not much that we can do from a promotional standpoint or anything until we have approval. When we talk about commercial prep, that's all around, we've continued to refine our pricing strategy and more market research work that we've been doing. I think that we've taken advantage of this gap between the launch of the filler and the expected approval of the neuromodulator to build further relationships with physicians at the customer level. We're continuing to establish the prestige Revance Therapeutics aesthetics brand. I think people see us now as a company that's working towards a broader range of products both from a services and a product stage. Obviously we talked about building inventory in advance of launch. A lot of the launch prep is internal activities, getting all of our sales materials ready and everything to support that. That's more of what we're doing on the commercial prep side. On the manufacturing side, we kind of broke protocol in commenting on where we were in our FDA journey given the pandemic when we talked about the fact that an inspection had not been scheduled prior to the PDUFA, and then again putting out a press release that one had been scheduled to occur before the end of June. I wouldn't read into my commentary about process. This is sort of a standard piece that needs to happen before approval. The next communication you'll hear from us is kind of once we get the FDA decision. Again, I come back to the fact that we feel very good about our prep and where we were in that process and we continue all of our preparations in the hopeful approval of the product. Next question. Thank you. Our next question comes from the line of David Amsellem from Piper Sandler. Your line is now open. Hey, thanks. First question is on the fillers. I don't know if you talked about this in your prepared remarks. I'm sorry if I missed it, but can you just talk about the mix among the different SKUs? Are there any that are predominating or are there any that have gained particular traction or that practices have a real affinity for thus far? I know it's still relatively early in the commercial life in these early days, but as things evolve, what are you seeing out there in the field? That's the number 1. Number 2, can you just remind us on DAXI, once you get approval, what sort of net are you going to cast in terms of training of injectors? In other words, how many should we expect you to have trained within the first 6 and say 12 months of the commercial life of DAXI? Over time, should we expect some sales force expansion given that there are more injectors of neuromodulators than there are of fillers? How should we think about that? Thanks. Great. Thanks, David. The first one on the mix side of it, we didn't address those in our scripted comments, but previously what we said last quarter was that it was roughly a third, a third, a third. We're not seeing a major shift between 2, 3 and 4. We're still early. I think people are still figuring out and I've been surprised at when we've been out in the field kind of the range of places that people are using it. Obviously we're limited to focusing on indications on the glabellar lines, but I think that we're finding folks use this for different performance characteristics and you'll hear from one party that they like the performance characteristics from RHA 2 and somebody else on RHA 4. Right now it's still pretty even. I'm sure we'll see some separation over time. Right now it continues to be pretty evenly split to third, a third, a third. In terms of our neuromodulator and kind of how we're thinking about the launch in 6-12 months post-launch, we remain committed to kind of this prestige and targeted strategy. What we've talked about before is that out of the 30,000-40,000 injector accounts that we think there are in the U.S., a top third of those are really the target that we're going after. That we would expect over time to be in roughly half of that top third. Right now we're in 2,000 accounts. Those are obviously going to be sort of our biased accounts to go after first because they leaned in with RHA because of the prestige strategy. They like the idea of no pricing and so that's the same group of customers that we expect are going to appreciate the differentiated value of our neuromodulator. We're still a little early to talk about exactly kind of the number of accounts that we expect to target over time. I think that starts getting a little bit more towards guidance. Phase 1 is going to be make sure that as the product's used commercially, that we're building from a position of strength in terms of the outcomes. After that, we'll sort of more broadly introduce it, certainly to the prestige accounts that have already expressed an interest with us. There's no doubt that there will be a broader number of accounts that I think are going to have an interest in leaning in with us once the neuromodulator's approved. Great. Thanks. Right. Thank you. Thank you. Thank you. Our next question comes from the line of Tim Lugo from William Blair. Your line is now open. Thanks for taking the question. I know most people on the phone have probably heard this question over the past few years. Ahead of hopefully an approval and launch of DAXI, I just wanted to revive the thoughts around physicians and how they want to see their patients more often, not less often. I don't agree with that view. Could you just refresh us with kind of what you're hearing from physicians who have used DAXI in the clinical trials and maybe some of the interest you're hearing from the field, from RHA? Just really an update on that thought of a long duration asset versus a short acting neurotoxin and the excitement around those. Yeah. Tim, as it relates to sort of the long duration profile that we've seen in clinical trials with our neuromodulator and sort of how that might fit into clinical practice and the impact of a couple data points that we'll bring out. There's a lot of market data out there that despite conventional neuromodulators lasting kind of 3 months, 4 months, that average consumers only come in sort of 1.9 times a year or less. First and foremost, we think it figures in very well to what the normal pattern is of consumers. Secondly, particularly with the prestige accounts that we're going after, when we've been out in the field, these folks, if anything, have long waiting lists. Getting into these accounts is a challenge. If you're a provider, the only way that you can necessarily increase sort of the services that you offer to your patients or increase profitability is if you can do more services at the same setting. A neuromodulator treatment every twice a year fits really well with also providing filler as well. This idea that you can add sort of both filler and neurotoxins together to give better outcomes to patients and increase the per visit ticket makes a ton of sense. In the customers that we're talking to, and obviously we've got a bias towards those that are leaning into the prestige strategy, it resonates a lot. The last thing I would say is, innovation for us underpins everything. What that does also is creates choice. Creates more choice at the physician level and at the consumer level. With a longer acting neuromodulator, we're not trying to be everything to everybody. If there are consumers in the practice that prefer coming in three, four times a year, and that's the case that they want, the practice wants it, that's great. Based on our market research, we think there's a not insignificant number of consumers that really will put a premium on a neuromodulator that lasts longer. We think practices being able to provide choice, figuring out what fits makes a lot of sense. We continue to feel really good about the value proposition and how this is going to fit into practices, both from a consumer demand and from a profitability standpoint. That's great to hear. Thank you for clarifying. Maybe my one follow-up. In the therapeutic category, I just don't understand why a long duration product would not capture a majority of share eventually in an indication like cervical dystonia. I know you're obviously adding to the therapeutic side of your franchise with the addition of Rob Bancroft, but can you maybe talk to some of the market research, and remind us about the market research in the therapeutic side? Sure Tim. No, I would say that's sort of what our market research shows as well. It actually shows that in the therapeutic area, that we could become a shared leader. I think it speaks to the fact that these are debilitating diseases and that the ability to reduce the frequency of visits obviously gives prolonged symptom relief, but it also takes some stress off of the system, right? It's less facility fee, physician time, and everything else. If you look at the data that we generated from our CD program, not only was the duration profile really strong, but we had a very encouraging safety signal as well with low dysphagia rates. We really are optimistic about our neuromodulator performance in clinical trials and therapeutics. That's why we announced some of the new hires that we have. We're starting to get ready for commercial introduction of our cervical dystonia indication and feel very good about the performance profile of the product in the therapeutic market. Thank you for the question. Thanks, Tim. Thank you. Our next question comes from the line of Balaji Prasad from Barclays. Again, our next question comes from the line of Balaji Prasad. Hi. Good afternoon, everyone. Thanks for the questions. Apologies if this has been asked before, but just want to go back to the number of accounts opened this quarter, or net accounts opened, 2,000, and try to extrapolate this as to what's likely to be the account opening run rate by the end of the year and how this could tie up to your eventual DAXI launch. Thanks. We reported sort of the total number of combined accounts between our services platform and our products, which is the RHA product line, at the end of each quarter. We talked about there being over 500 at the end of Q3, over 1,000 at the end of Q4, over 1,500 at the end of Q1, and now over 2,000 at the end of Q2. We've been averaging 500 or so new account adds per quarter. Obviously, with some of the new products and programs that we have coming out, we'll need to sort of look to say if account activation is important as doubling back and making sure that with some of these new services, that we're going deeper in the existing accounts. I think those are reasonable numbers for now. I think post-approval of our neuromodulator, we'll need to revisit that because again, our strategy is much more versus deep versus wide. We clearly have a lot of run room in the accounts that we view to be our target market opportunity. With this tracking right now, it's not unreasonable to sort of look at 500 new account adds per quarter as something that could continue to exist for the balance of the year. Thanks, Mark. That's helpful. Maybe a quick one on biosimilar BOTOX to just see where you are post your submission. Sorry, this is with regard to the FDA data package that was submitted a couple of months ago. On the biosimilar, what we indicated was that the next step in that program is to have a meeting with the agency to determine the phase III program that would be required for approval. We expect that to happen before year-end. I know that Viatris has their own conference call coming up soon. They might give a little bit more commentary on it. We continue to be encouraged by the dialogue that we've had with them. Again, there will be a meeting with the agency to lay out sort of what that program's going to look like before year-end. Got it. Thanks, Mark. Great. Thank you. Thank you. Our next question comes from the line of Serge Belanger from Needham & Company. Your line is now open. Hey, good afternoon. Thanks for taking my questions. First one for Mark. Can you just give us a refresher of the open label safety study in cervical dystonia from which you'll be reporting results in the second half? If I recall, patients are eligible to receive multiple courses of treatment, so maybe just give us an idea of what you'll be looking for in terms of efficacy, duration, and safety. Yes. On the open label safety study, it was really a dose escalation study looking at primary endpoint there was to look at the safety of sort of repeat doses over time. When we report that out, it's much more of a looking at the safety profile of the product and how patients respond to, again, these different doses that occur over time and an increase in doses if that's what the clinicians ultimately decide. It's less about sort of the duration profile and more about the safety side of it. That's what we'll be reporting out on that. Okay. Secondly, with the addition of Rob Bancroft to the therapeutics team, should we look at that as a kind of a confirmation that you're moving forward with a commercialization effort for the muscle movement disorder in lieu of a commercial partnership? Yeah, that's correct. In addition to Rob, we also announced last quarter the addition of another senior level person on the healthcare reimbursement side of it, so that we're focusing on that as well. We've long talked about our focus on building out sort of a direct sales force in the muscle movement space. These are some of the key pieces that we're putting in place to allow us to access and enter that market. As it relates to cervical dystonia, we talked about a filing in 2022 and an approval in 2023, so it's not too far away, and we believe that there's a fair bit of opportunity to be unlocked there. As we talked previously, we think that the performance profile of our product will allow us to be very competitive in the therapeutic category. Thank you. Thank you. Our next question comes from the line of Ken Cacciatore from Cowen. Your line is now open. How you doing, team? Congratulations. Just really great performance without yet having DAXI. As we think forward, I know, Mark, you want to be thoughtful in terms of how the product is rolled out, the experience and the initial experience some of the kind of key users have. Can you talk a little bit about now that AbbVie has taken over control of the BOTOX franchise, kind of anything that they're doing different that maybe you all could apply or as you step back and look at the overall marketplace, in terms of timing for you all and DTC and really differentiating this product as we think through maybe the latter part of 2022, not necessarily the near term. Is there kind of any nuances you can give us as you approach this market that maybe has been different in the past that we're going to try to do a little bit different in the future? Thanks so much. Sure. Thanks again. No, not really. Obviously, as the market leader, they talk a lot about sort of increasing DTC $. They've got a big push into training new injectors, so they're going to expand sort of the number of folks that are actually doing toxin treatments. Our strategy's a little different, right? We're going after sort of the top of the pyramid on that side of it. I think all of these things happening in concert are no doubt going to help grow the overall market. We would expect that they're going to continue to run their playbook. More awareness $, more couponing to customers, training of new injectors, all of which will help grow the market. As we come into the market with innovation, we will also drive more consumer awareness for coming in, but ours is going to be much more focused, again, on these kind of prestige and high-end practices. We don't expect a whole lot different in terms of the way that we view the market. Certainly, once we hit the market, I'm sure it's going to be quite competitive, but both of us will have the playbooks that we'll run once we get there. From an overall approach to the market, I don't see any major differences from that standpoint. Thanks much. Thanks. Thank you. As a reminder, to ask a question, you will need to press star, then the number one on your telephone. That's star one on your telephone. Our next question comes from the line of Vamil Divan from Mizuho. Great. Thanks for taking the question. Maybe just a couple from me. One on the PayFac integration that you've talked about for next quarter. Can you maybe just provide a little more insight as to the benefits you think that's going to provide on that side of your business? The second part would just be maybe any update you might have around your efforts around migraine. I know you've talked about that being a matter of sort of when you work on that as opposed to if you work on that. Just curious if there's anything new as that market obviously is evolving pretty rapidly as well. Any new thoughts would be helpful. Thanks. Great. Thanks, Vamil. First on the PayFac side of it. The real advantage of PayFac, in addition to participating in more of the overall margin stream of the credit card processing, the big advantage is it gives us access to the source level data. Right now, the HintMD system is a robust credit card processor, but it doesn't necessarily give us access to the source level data. Things around data analytics and insights and even automating subscription services in a way that's seamless and easy to set up and white label loyalty become a lot harder if you don't have access to the source data. By becoming a payment facilitator, we then are able to scrape that source data, which again, it'll be the practice's information, but then we can turn around and use that to help them with data insight and analytics. That's really the key functionality piece that's going to enhance. We're very encouraged with how the beta launch of that is going and how it's performing and again, that will be sort of the foundation that we'll build out these other services on top of. Again, it will allow us the ability to participate in a little bit more margin spread, if we choose to hold onto that or if we choose to give it back to the practices. On the migraine side of it, to your point, we've talked about it sort of not as if and a when, and I think what we said most recently is that we would sort of consider this as part of our 2022 planning cycle. We'll be, I think, better prepared to address sort of where migraine fits into our overall therapeutic strategy and what priorities that we have ultimately for 2022, when we give a little bit more color on our 2022 operating plan. Okay. All right. Thank you. Great. Thanks, Vamil. Thank you. Our next question comes from the line of Doug Tsao from H.C. Wainwright. Your line is now open. Hi, everyone. Chris Bialas here on for Doug Tsao. Congrats on the quarter. I was just a little bit interested in the prestige segment that you're targeting for DAXI now. A competitor of yours is heavily targeting the millennial demographic, I was just wondering how much overlap there is between these two segments. Thanks. Chris Bialas, this is Dustin. I think we need to separate the segmentation around consumer and then separation around practice. The prestige strategy is around our focus really on partnering with those practices that drive value through the experiences they provide their patients, as well as the outcomes they provide their patients. Those practices see all patient types. Those might be millennials, Gen Zs, and all in between. Our strategy is really different from the others in that we believe we can build the most amount of loyalty directly to those practices by providing that experience with us and great innovative product. The consumers that they treat will be loyal to the practice. Our loyalty really lies in driving it to those practices. Those practices will see all the millennials that'll be coming into the space just as much as the other practices. Awesome. That's very helpful. Thank you. Thanks, Chris. Thank you. We don't have any further questions. I would now like to hand the call back to Mark Foley. Thank you, operator. Before I make my closing comments, I just wanted to recap some of our therapeutic milestones for the second half. My understanding is that the sound quality for that section was not great. In the second half of this year, we expect to share the results from our ASPEN open label long-term safety study. Afterwards, we plan on filing a supplemental Biologics License Application in 2022 with anticipation in 2023. Again, that's for our cervical dystonia program. Our clinical team is also preparing for a phase III program in adult upper limb spasticity. You'll recall that we completed our JUNIPER phase II study in February of this year, and our plan remains to hold an end of phase II meeting with the FDA before year end. To close things out, in the coming months, we plan to virtually attend the Citi and Wells Fargo healthcare conferences. We welcome your request for meetings at these events or directly through us. Feel free to reach out to Jessica if you'd like to schedule some time. With that, I'd like to thank all of you for participating in today's call. Thanks. Ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.